Claim Missing Document
Check
Articles

Found 2 Documents
Search

Exploring the potential of Laportea decumana extract compounds as COX-1 and COX-2 inhibitors: An in silico study Simaremare, Eva S.; Kurniawan, Fransiska; Hartati, Rika; Tjahjono, Daryono H.
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narraj.v5i1.1627

Abstract

Laportea decumana (Roxb.) Wedd., known as itchy leaves, is traditionally used for pain relief due to its bioactive compounds. However, previous studies were limited by resource-intensive in vivo methods and a lack of mechanistic insights into cyclooxygenase (COX)-1 and COX-2 binding. The aim of this study was to identify compounds in the n-hexane and ethyl acetate extracts of L. decumana with potential as COX-1 and COX-2 inhibitors and to predict their binding affinity and stability within the binding pocket through molecular dynamics simulations. Leaves collected from Arso, Keerom Regency, Papua, Indonesia, were dried, sieved into simplicia, and macerated with n-hexane to obtain a n-hexane extract. The residual simplicia was further macerated with ethyl acetate to produce an ethyl acetate extract. N-hexane extract compounds were analyzed by gas chromatography-mass spectrometry (GC-MS), and ethyl acetate extract compounds by liquid chromatography-mass spectrometry (LC-MS). Identified chemicals were used in in silico evaluations targeting COX-1 and COX-2. This study identified ten compounds with high performance in docking analysis, which were further evaluated by molecular dynamics. The n-hexane extract contained 31 compounds, while the ethyl acetate extract contained 27. Among these, 4,8,12,16-tetramethylheptadecan-4-olide from the n-hexane extract demonstrated the strongest affinity for both COX-1 and COX-2, with binding free energies of -41.62±1.03 kcal/mol and -33.05±0.11 kcal/mol, respectively. Its interactions were comparable to those of native ligands, with superior binding free energy. In the ethyl acetate extract, pseudosantonim demonstrated the highest affinity for COX-1 (-24.41±1.32 kcal/mol), while arteamisinine showed strong potential as a COX-2 inhibitor (-23.53±0.30 kcal/mol). In conclusion, 4,8,12,16-tetramethylheptadecan-4-olide was the most potent COX-1 and COX-2 inhibitor, pseudosantonim was the most effective COX-1 inhibitor, and arteamisinine demonstrated COX-2 inhibitory potential. Further validation through in vitro or in vivo studies is recommended.
Phytochemical and Pharmacological Review of Arcangelisia flava (L.) Merr: Insights into Its Bioactive Compounds and Therapeutic Potential Yabansabra, Yuliana Rut; Bowaire, Anike; Simaremare, Eva S.; Yaam, Demas R.; Tiris, Aira; Nadeak, Erpina S.M.
Jurnal Biologi Papua Vol 17 No 1 (2025)
Publisher : Jurusan Biologi FMIPA Universitas Cenderawasih

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31957/jbp.4508

Abstract

Arcangelisia flava (L.) Merr., commonly known as kayu kuning, is a medicinal plant traditionally used in Southeast Asian medicine. Various studies have identified bioactive compounds such as furanoditerpenes, alkaloids, flavonoids, tannins, and phenolic compounds that contribute to its pharmacological activities, including antimicrobial, antioxidant, and antidiabetic effects. Despite the growing body of research on its pharmacological potential, the mechanisms of action of these bioactive constituents remain inadequately understood, and clinical evidence supporting its use in modern therapy is still limited. This systematic review compiles data from diverse scientific sources, focusing on the phytochemical composition, extraction methods, pharmacological activities, and comparisons with conventional pharmaceutical agents. The analysis revealed that A. flava contains various bioactive constituents responsible for its therapeutic effects. Furanoditerpenes demonstrate antimicrobial and antifungal activity, while alkaloids and phenolic compounds exhibit significant antioxidant and antidiabetic properties. Extraction techniques varied across studies, affecting the efficiency of bioactive compound isolation. Comparisons with standard pharmaceuticals suggest that A. flava extracts exhibit comparable efficacy in several pharmacological domains. These findings indicate that A. flava holds considerable promise as a natural therapeutic agent. However, further investigations are needed to clarify its pharmacological mechanisms through pharmacokinetic and pharmacodynamic studies, as well as clinical trials to confirm its safety and effectiveness in human applications. The integration of modern technological approaches such as metabolomics and bioinformatics could facilitate the identification, standardization, and development of phytopharmaceutical products derived from A. flava, thereby advancing its potential use in evidence-based medicine.